Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 22,14:00-17:10
Nanobody Drug R&D Session
Stay tuned
Haikun Shi(Planner):Founder & Chairman, Kunyu Biotech
Haikun Shi(Host):Founder & Chairman, Kunyu Biotech
14:00-14:05 Opening Speech
Changchun Zha:Chairman, Biointron
14:05-14:20 Progress of Nanobody‑based Therapeutics & Applications in ADCs
Haikun Shi:Founder & Chairman, Kunyu Biotech
14:20-14:35 Bispecific Nanobodies Targeting TROP2 and c-Met
Wenxin Luo:Professor, School of Public Health, Xiamen University; Leader, Antibody Engineering Group, National Engineering Research Center for Diagnostic Reagents and Vaccines of Infectious Diseases
14:35-14:50 R&D Progress and Challenges in Nanobody-Based Radiopharmaceuticals
Tao Xu:Founder & CEO, SmartNuclide
14:50-15:05 Development of Nanobody Therapeutics for Diabetic Nephropathy
Jiajun Fan:Director & Principal Investigator, Institute of Biotech Pharmaceuticals, Quzhou Fuda Biomedical Innovation Institute; Shanghai Rising-Star Young Scientist
15:05-15:20 Applications of Diverse Screening Platforms in Nanobody Discovery
Lei Shi:Senior Vice President, Biointron
15:20-15:40 Dual‑Epitope Nanobodies for Acute Disease Therapy Strategies
Mingyue Huang:Founder, Chairman & CEO, BiyoPharma
15:40-15:55 Break
15:55-16:10 Cross-Species Reactive CD3 Nanobody: Fapon TCE Platform and Its Applications
Di Lu: Vice President of R&D, Fapon Biotech
16:10-16:25 Next-Generation chVHH Nanobodies: Novel Discovery Strategies and Platform Practices for Drug R&D
Lanqing Han:Chairman, Cyagen Biosciences; Director, Artificial Intelligence Innovation Center, Tsinghua Pearl River Delta Research Institute
16:25-17:10 Roundtable:Challenges and Future of Next‑Generation Antibody Drugs
Haikun Shi (Host):Founder & Chairman, Kunyu Biotech
Shuqing Chen:Professor & Doctoral Supervisor, College of Pharmaceutical Sciences, Zhejiang University; Founder & Chairman, Neoantigen
Wenxin Luo:Professor, School of Public Health, Xiamen University; Leader, Antibody Engineering Group, National Engineering Research Center for Diagnostic Reagents and Vaccines of Infectious Diseases
Jing Huang:COO & CBO, Novamab
Mingyue Huang:Founder, Chairman & CEO, BiyoPharma